9/24/2010 S U ts n ) s tie a 4.7 illio (m 3.5 ilu rt F a Outpatient e H Inpatient * 50 s 60 s 70 s >80
|
|
- Daniella Cox
- 5 years ago
- Views:
Transcription
1 Exciting Times: Advances in Heart Failure Dana McGlothlin, MD Associate Professor of Medicine Advanced Heart Failure and Transplant Program Medical Director, CCU Overview HF Statistics Therapies for chronic HF Management of acute decompensated HF (ADHF) Intravenous inotropes, vasodilators, diuretics AVP antagonists Ultrafiltration Investigational HF therapies Surgical therapies Stem cells Advanced therapies for stage D HF Transplantation Mechanical assist devices Heart Failure Statistics in 2010 % US prevalence: 5.8 million US annual incidence: 670,000 Annual mortality: 282,754 Cost: $39.2 billion 15 0 HF increases with age 50 s 60 s 70 s >80 et al. Circulation 2010;121:e46-e215 Outpatient Inpatient Cost Distribution for HF Heart Failure Patients in US (millions) HF Prevalence Projections: An Increasing Problem *Rich M. J Am Geriatric Soc. 1997;45: American Heart Association Heart and Stroke Statistical Update American Heart Association. Heart Disease and Stroke Statistics 2003 Update. Dallas, Tx: American Heart Association; * 1
2 ACC/AHA Staging System Evidence-Based Treatment Across the Continuum of Systolic LVD and HF A B C D Stage High risk for developing heart failure (HF) Asymptomatic HF Symptomatic HF Refractory end-stage HF Hunt SA, et al. Circulation 2001;104: Patient Description Hypertension Coronary Optimal drug artery therapy disease Aspirin, ACE inhibitors, statins, β-blockers, Diabetes α-β-blockers mellitus (carvedilol) diabetic therapy Family history of cardiomyopathy Previous myocardial infarction Optimize drug therapy Left ICD if ventricular LV dysfunction (systolic) dysfunction present Asymptomatic valvular disease Known Optimize structural drug therapy heart disease Shortness ICD if LV dysfunction of breath (systolic) and fatigue present CRT (if QRS wide, LVEF<35%) Reduced exercise tolerance Optimize drug therapy IV inotropes ICD/CRT-D IABP Other devices (LVAD, ECMO) Marked symptoms at rest despite maximal medical therapy (e.g., those who are recurrently hospitalized or cannot be safely discharged from the hospital withot specialized interventions) Control Volume Diuretics Renal Replacement Therapy* Aquaretics Ultrafiltration* *In selected patients Improve Clinical Outcomes ACEI Aldosterone β-blocker or ARB Antagonist or ARB CRT ± an ICD* HDZN/ISDN* Treat Residual Symptoms Digoxin What s new in medical therapy for HF? Ivabradine vs placebo in HF: SHIFT Study High resting heart rate is a risk factor for adverse outcomes Ivabradine is a selective sinus node inhibitor 6558 pts with stage C HF LV EF <35% HR > 70 bpm Hospitalized for HF in past year Stable HF meds Ivabradine vs placebo in HF: SHIFT Study Outcomes-promising! Outcomes in SHIFT CV death or HF hospitalization Death from heart failure Ivabradine, Placebo, n=3241 (%) n=3264(%) HR (95% CI) ( ) < ( ) HF hospitalization ( ) < CV death, HF hospitalization, or admission for nonfatal MI Swedberg K et al. Lancet ( ) 0.89) < SEs: fewer w/ ivabradine than PBO, except 5% had Sx brady w/ ivabradine vs 1% w/ PBO p 2
3 HFSA 2006 Practice Guideline (12.3, Table 12.3) Acute Decompensated Heart Failure (ADHF) Treatment Goals for Hospitalized Patients Improve symptoms, especially congestion and low-output symptoms Optimize volume status Identify etiology Identify precipitating factors Optimize chronic oral therapy; minimize side effects Identify who might benefit from revascularization Educate patients concerning medication and HF self-assessment Consider enrollment in a disease management program Strength of Evidence = C HFSA 2006 Practice Guideline ( ) Overview of Treatment Options for Patients with Acute Decompensated HF Fluid and sodium restriction Diuretics, especially loop diuretics Ultrafiltration/renal replacement therapy (in selected patients only) Parenteral vasodilators * (nitroglycerin, nitroprusside, nesiritide) Inotropes * (milrinone or dobutamine) *See recommendations for stipulations and restrictions. Adams KF, Lindenfeld J, et al. HFSA 2006 Comprehensive Heart Failure Guideline. J Card Fail 2006;12:e1-e122. More than 50% of Patients Have Little or No Weight Loss During Hospitalization Diuretics: Adverse Effects Patients (%) % N=26,757 6% 13% Fonarow GC. Rev Cardiovasc Med. 2003;4(suppl 7): % 33% 15% (<-20) (-20 to -15) (-15 to -10) (-10 to -5) (-5 to 0) (0 to 5) (5 to 10) (>10) Change in Weight (lbs) Current treatment options Loop diuretics IV inotropes Nitrates Nesiritide 3% 2% ADHERE Registry data Hypo K+, Na+, Mg+ (15-60%) Stimulation of neurohormonal activity Hyperuricemia (15-40%) Hypotension Alkalosis Ototoxicity GI upset Sharpe N. Heart failure. Martin Dunitz 2000;43 Kubo SH, et al. Am J Cardiol 1987;60:1322 MRFIT, JAMA 1982;248:1465 Pool Wilson. Heart failure. Churchill Livinston 1997;635 3
4 Arginine Vasopressin and CHF Arginine vasopressin (AVP) acts via V1a, V1b, and V2 receptors vasoconstriction, inotropic effects, H2O retention Neurohormal activation of AVP is clinically important Hyponatremia and hypervolemia AVP-2 receptor antagonism facilitates aquaresis without disturbances of electrolytes and EVEREST Trial: RCT of oral Tolvaptan 30mg qd vs PBO in pts hospitalized w/ ADHF 2 concurrent trials (Trial A: n=4048 pts and Trial B: n=2085 pts) in No. America, So. America, and Europe Primary endpoint: composite of changes in global clinical status and body weight at day 7. Results: Primary composite endpoint was met, improved many secondary endpoint HF signs and symptoms Selected Secondary end points in EVEREST outcomes trial End point Mean change in body weight at day 1 (kg) Patients showing improved dyspnea scores at day 1* (%) Mean change in serum sodium at days 1/7** (meq/l) Patients showing >2 grade improvement in edema* (%) Trial A Tolvaptan PBO p Trial B Tolvaptan PBO p < < < < / / *Limited to patients with symptom at baseline **Limited to patients with baseline levels <134 meq/l Konstam MA et al. American College of Cardiology 2007 Scientific Sessions; March 25, 2007; New Orleans, LA. Special Session Late-Breaking Clinical Trials I. Proportion Alive EVEREST: All-Cause Mortality Median follow-up 9.9 months Peto-Peto Wilcoxon Test: P=0.68 Months In Study HR 0.98; 95%CI ( ) Meets criteria for non-inferiority TLV 30 mg PLACEBO TLV PLC Proportion Without Event EVEREST: CV Mortality or HF Hospitalization Peto-Peto Wilcoxon Test: P= TLV PLC Months In Study HR 1.04; 95%CI ( ) TLV 30 mg PLACEBO
5 Ultrafiltration to Manage Congestion Ultrafiltration Does not remove sodium and other electrolytes (aquafiltration) Does not activate neurohormones Can safely improve hemodynamics Requires a central venous catheter and anticoagulation UNLOAD Trial: Freedom From Heart Failure Rehospitalization Device therapies for chronic HF Costanzo, M. R. et al. J Am Coll Cardiol 2007;49:
6 SCD Primary Prevention Trials in HF MADIT-I MADIT-IIII CABG Patch MUSTT DINAMIT CAT AMIOVERT Who Should Get an ICD? Nonischemic cardiomyopathy: NYHA class II to III sx LVEF < 35% Ischemic cardiomyopathy: NYHA class II to III sx LVEF < 35% At least 40 days post-mi (DINAMIT) No reversible ischemia No recent revascularization Bardy GH et al. NEJM ;352(3): Cardiac Resynchronization Therapy CRT: CARE-HF Trial Randomized, controlled trial of 813 patients Entry criteria: IVCD NYHA III or IV CHF LVEF <35% Outcomes: Decreased mortality: 8.1% vs 13.9% at 29 months At 90 days: Improved quality of life (NYHA class 2.1 vs 2.7) Cleland JGF, et al. NEJM 2005; 352(15):
7 Outcomes in CARE-HF: 409 CRT-treated patients as compared with 404 control patients Outcomes All-cause mortality/unplanned hospitalization for CV event Hazard ratio (95% CI) 0.63 ( ) 0.77) All-cause mortality 0.64 ( ) 0.85) All-cause mortality/hf hospitalization 0.54 ( ) 0.68) p < <0.001 CRT: Recommendations Indicated for patients with LBBB or IVCD and: LVEF < 35% Sinus rhythm NYHA III-IV IV symptoms despite optimal medical mgmt These patients are also candidates for ICD placement and should be considered for a dual- function device (CRT-D) J Am Coll Cardiol Sep 20;46(6): Cleland JGF et al. N Engl J Med 2005; 352: Surgical Therapies Surgical Ventricular Reconstruction: STICH Trial Rationale: Left ventricular remodeling after MI can lead to progression of HF and poor prognosis Surgical LV volume reduction may improve HF outcomes in pts with ICM STICH: Surgical Tx for IsChemic Heart failure 1000 pts with EF <35%, CAD amenable to CABG, incl LAD dz amenable to revasc Randomized to CABG alone vs CABG + SVR Primary outcome: Composite of death from any cause and hospitalization for cardiac causes Jones, RH. NEJM 2009;360(17):1705 7
8 Surgical Ventricular Reconstruction STICH Trial Jones, RH. NEJM 2009;360 STICH Trial STICH Trial 8
9 ACORN Novel Mechanical Anti-remodeling Therapies in Heart Failure: Cardiac Support Devices HeartNet PEERLESS HF Trial Multicenter RCT of 217 patients with chronic advanced HF despite max med/device therapy ACC/AHA Stage C HF Stable medical/device therapy x3 mo LVEF<35% Randomized to HeartNet device or continued med/device therapy Safety and efficacy Primary endpoints Pk VO2, 6 MWD, QoL at 6 mo Freedom from all-cause mortality at 12 mo Results Study halted early d/t lack of effect on clinical endpoints, including Pk VO2 Survival was equivalent between the two groups Modest effect on ventricular remodeling by echo parameters Presented at HFSA 2010 in San Diego Stem cell Transplant in chronic heart failure: STAR-heart trial Prevention and/or reversal of remodelling of the LV by cell therapy is a hot topic and has generated great interest Studies of skeletal myoblast transplantations in HF patients has been associated with serious safety concerns from arrhythmias (MAGIC and MARVEL-1) Prior human studies using autologous bone marrow cells (progenitor cells) have been conflicting, with fewer safety concerns, but data in chronic HF is lacking STAR-heart Study evaluated the changes in LV geometry and survival in chronic HF patients Open label study of 391 pts with LVEF <35% due to ICM enrolled between Strauer B et al. Eur J Heart Fail 2010;12: Study design: patient recruitment. Strauer, B. Eur J Heart Fail. 2010;12:721 Published on behalf of the European Society of Cardiology. All rights reserved. The Author For permissions please journals.permissions@oxfordjournals.org. 9
10 STAR-heart Study Results: Changes in LVEF Stem Cells in Chronic Ischemic HF: STAR Heart Survival Effect of bone marrow cell therapy on survival in patients with chronic ischaemic cardiomyopathy. Strauer B et al. Eur J Heart Fail 2010;12: Published on behalf of the European Society of Cardiology. All rights reserved. The Author For permissions please journals.permissions@oxfordjournals.org. Cardiac Transplantation Advanced therapies for ACC/AHA stage D HF Remains the most effective Tx for end- stage heart disease, although donor shortage limits its use 1-year survival: 86% (2002) 5-year survival: 71% 10-year survival: 46% Taylor et al. J Heart Lung Transplant 2003;22:
11 Trends in Heart Transplants (UNOS: ) Destination Therapy Trials Number of Transplants 2,500 2,000 1,500 1, ,363 2,107 2,199 2, Years Source: United Network for Organ Sharing (UNOS), scientific registry data. Fang JC NEJM 2009 Newer Devices on the Horizon Conclusions The prevalence of HF is increasing rapidly as the population grows older Proven therapies that reduce morbidity and mortality with HF are ACE-I/ARB, BB, Aldosterone antagonists, hydralazine, nitrates, CRT (for patients with IVCD), ICD Ivaradibine, a selective sinus node inhibitor, is showing some promise in the treatment of chronic HF Short term aquaresis with Tolvaptan can improve HF symptoms without electrolyte disturbances in ADHF but does not improve survival Ultrafiltration is a safe and effective way of treating congestion in ADHF without activing the neurohormonal system 11
12 Conclusions Surgical therapies for ventricular reconstruction and prevention of remodeling have not yet been effective Stem cell therapy (autologous bone marrow cells), not skeletal myoblasts is showing some efficacy in HF, probably by a paracrine mechanism rather than cell transformation, but needs to be tested in a RCT Thank You! Transplant still has the best outcomes for treatment of stage D HF, however VADs are the way of the future Stay tuned! 12
Advanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More information3/2/2017. Identifying the Patient for Advanced Therapies. Why is Identifying the Adv HF patient important? CHF Stages and Steps of Treatment
Identifying the Patient for Advanced Therapies Cindy Bither Chief NP- Adv HF Program Medstar Heart and Vascular Institute Stage A High risk with no symptoms Stage B Structural heart disease, no symptoms
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationReducing 30-day Rehospitalization for Heart Failure: An Attainable Goal?
Reducing 30-day Rehospitalization for Heart Failure: An Attainable Goal? Ileana L. Piña, MD, MPH Professor of Medicine, Epi/Biostats Case Western Reserve University Graduate VA Quality Scholar Cleveland
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationState of the Art Treatment - Hyponatremia, Heart Rate, et al
State of the Art Treatment - Hyponatremia, Heart Rate, et al Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationNew Strategies For Treating Patients With Chronic Heart Failure
New Strategies For Treating Patients With Chronic Heart Failure Barry Greenberg MD Professor of Medicine Director, Advanced Heart Failure Treatment Program University of California, San Diego Disclosures
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationGerasimos Filippatos MD, FESC, FCCP, FACC
Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of
More informationUri Elkayam, MD. Professor of Medicine University of Southern California Keck School of Medicine
Mihai Gheorghiade, MD Memorial Lecture Use of Vasopressin Antagonists for the Management of Hyponatremia and Volume Overload Uri Elkayam, MD Professor of Medicine University of Southern California Keck
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationThe Role of Information Technology in Disease Management: A Case for Heart Failure
The Role of Information Technology in Disease Management: A Case for Heart Failure Teresa De Peralta, MSN, APN-C Heart Failure Product Workflow Consultant Medtronic Population Management Level 3: As patient
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationHyponatremia in Heart Failure: why it is important and what should we do about it?
Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationIntegrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure
Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure J. Herbert Patterson, Pharm.D., FCCP One of Four Continuing Education Programs in the Series, Acute Decompensated
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationSliwa et al. JACC 2004;44:
TREATMENT OF ADVANCED HEART FAILURE HEART DISEASE IN KENTUCKY Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac
More informationWHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine
WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data Safety Monitoring Board SOPRANO (J&J), EVALUATE-HF
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationCASE STUDIES IN ADVANCED HEART FAILURE
CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationRevascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability
Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability 22nd Annual Heart Failure 2018: an Update on Therapy April 2018 Eric J. Velazquez, MD, FACP, FACC, FASE,
More informationThe Interface of Cardiology and Palliative Medicine
The Interface of Cardiology and Palliative Medicine Nathan Goldstein, MD Associate Professor Hertzberg Palliative Care Institute Brookdale Department of Geriatrics and Palliative Medicine Mount Sinai School
More informationRate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.
Article ID: WMC004618 ISSN 2046-1690 Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications. Peer review status: No Corresponding
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationAcute heart Failure. Critical cardiac care: update Markku S. Nieminen Helsinki, Finland. M S Nieminen, AHF ,ESC Stockholm
Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen Helsinki, Finland M S Nieminen, AHF 300810,ESC Stockholm Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen
More informationHeart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationSevere Left Ventricular Dysfunction: Evolving Revascularization Strategies
Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern
More informationIN-HF on line: patient settings (Enrollement period= )
IN-HF on line: atient settings (Enrollement eriod= 1995-2018) N of centers (total) 187 N of centers (ts. AHF only) 13 N of centers (ts. CHF only) 71 N of centers (both ts. AHF and CHF) 103 N of atients
More informationEpidemiology of Symptomatic Heart Failure in the U.S.
William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology Director, Division of Cardiovascular Medicine Deputy Director Davis Heart and Lung Research Institute
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationEvaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationDobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure
Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure Yuksel Cavusoglu, KU Mert, A Nadir, F Mutlu, E Gencer, T Ulus, A Birdane
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationMortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials
Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationIs Heart Rate a Treatment Target?
Is Heart Rate a Treatment Target? M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin) Universitätsklinikum des Saarlandes Homburg/Saar michael.boehm@uks.eu Heart Rate
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationLarge RCT s of CRT 2002 to present
Have We Expanded Our Use of CRT for Heart Failure Patients? Sana M. Al-Khatib, MD, MHS Associate Professor of Medicine Electrophysiology Section- Division of Cardiology Duke University Potential Conflicts
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More information